Structure Therapeutics appoints Angus Russell to Board, Audit Committee

Structure Therapeutics Inc.

Angus Russell appointed Class I director effective Aug 26, 2024; term expires at 2027 annual meeting.
Russell joins Audit Committee; Ted Love, M.D. transitioned off the Audit Committee.
Granted option for 75,000 ordinary shares (25,000 ADS) vesting over 36 months.
Annual cash retainers: $45,000 for Board service plus $10,000 for Audit Committee, prorated for 2024.
Board determined Russell independent under Nasdaq standards and meets audit committee requirements.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Angus Russell

Class I director

GPCR · Structure Therapeutics Inc.

Effective: 2024-08-26
Filed: August 27, 2024, 7:59 PM ET

appointed Angus Russell to the Board, effective August 26, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Angus Russell was appointed as Class I director at Structure Therapeutics Inc..

Action: appointed
Role: Class I director

Exact text from the filing

appointed Angus Russell to the Board, effective August 26, 2024.

View on SEC.gov

Structure Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-093434

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.